VIR Q2 2024 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-19.0% YoY

Gross Profit

-$102M-3320.0% margin

Operating Income

-$159M-5158.7% margin

Net Income

-$138M-4500.1% margin

EPS (Diluted)

$-1.02

QoQ Revenue Growth

-94.5%

Cash Flow

Operating Cash Flow

-$78M

Free Cash Flow

-$79M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$236M

Stockholders' Equity

$1.4B

Cash & Equivalents

$297M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-19.0%
Gross Profit	-$102M	-$164M	+37.9%
Operating Income	-$159M	-$215M	+26.3%
Net Income	-$138M	-$195M	+29.0%

Revenue Segments

Grant

$2M69%

Contract Revenue

$886,00029%

Collaboration Revenue

$55,0002%